Trend
DailyUptrend (starting)
4 hourSymmetric Triangle
1 hourLeaning Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns down below $0.90
Key levels
Resistance$5.26
Resistance$4.25
Support$3.86
Support$3.47
Latest news & SEC filings
EarningsArmata Pharmaceuticals posts smaller quarterly loss and higher revenue than expected
SEC FilingArmata Pharmaceuticals, Inc. filed a report on a major company event (Form 8-K)
All ARMP news →Armata Pharmaceuticals develops virus-based medicines called bacteriophages to fight bacterial infections that resist standard antibiotics. Its lead candidates are AP-PA02, given by inhalation for chronic Pseudomonas aeruginosa lung infections in people with cystic fibrosis or bronchiectasis, and AP-SA02, given intravenously for Staphylococcus aureus bloodstream infections. The company runs a production site in Los Angeles and works with outside organizations, including a cystic fibrosis nonprofit and a federal defense agency.
Based on the company's 10-K filed Mar 25, 2026.
NYSE · Healthcare
SEPT Low Target
$15.00
SEPT Mid Target
$15.00
SEPT High Target
$15.00
Analyst Consensus
$15.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ARMP.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$15.00
17
Moat Score
NONE
3/9
Piotroski Score
-10.4
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-439.33%
FCF Growth YoY
33.3%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for ARMP, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:08 | $3.72 | 1,651 | $$6K | SELL |
| 16:10:00 | $3.59 | 2,697 | $$10K | BUY |
| 15:32:34 | $3.72 | 1,310 | $$5K | BUY |
| 16:29:15 | $3.68 | 1,000 | $$4K | BUY |
| 16:15:01 | $3.66 | 1,972 | $$7K | MIDPOINT |
5 dark pool trades shown · $$32K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Armata Pharmaceuticals, Inc. (ARMP) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Armata Pharmaceuticals, Inc. (ARMP) is at $3.87, up 4.03% (+$0.15) at the Nov 13, 2026 close.
Latest ARMP news — Nov 12, 2026: Armata Pharmaceuticals posts smaller quarterly loss and higher revenue than expected · Nov 12, 2026: Armata Pharmaceuticals, Inc. filed a report on a major company event (Form 8-K)
The average analyst price target for ARMP is $15.00, ranging from $15 to $15, based on 1 analysts.
Analyst ratings for ARMP: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
ARMP last reported on Aug 12, 2026: EPS -$0.27 vs -$0.45 expected — a beat of 39.3%.
ARMP does not currently pay a dividend.
Support: $3.86, $3.47, $2.94. Resistance: $4.25, $5.26, $16.34.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 12, 2026: Armata Pharmaceuticals posts smaller quarterly loss and higher revenue than expected · Nov 12, 2026: Armata Pharmaceuticals, Inc. filed a report on a major company event (Form 8-K)